Equities

Cryosite Ltd

CTE:ASX

Cryosite Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.85
  • Today's Change-0.02 / -2.30%
  • Shares traded61.20k
  • 1 Year change+13.33%
  • Beta0.3264
Data delayed at least 20 minutes, as of Apr 26 2024 01:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cryosite Limited is engaged in providing outsourced clinical trials depot services. The Company manages the entire clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution and reverse logistics management. Its segments include Clinical trials and biological services logistics and Cord Blood and tissue storage. The Clinical trials and biological services logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, biological services and cell gene therapies depot services. Cord Blood and tissue storage segment provides storage of cord blood and tissue samples. Its facilities are purpose-built to store a range of biological materials, including Cell Banks (MCB, WCB), Mesenchymal Stromal Cell (MSC) Therapies, Tumour-Infiltrating Lymphocyte Therapies and others.

  • Revenue in AUD (TTM)12.61m
  • Net income in AUD1.58m
  • Incorporated1999
  • Employees34.00
  • Location
    Cryosite Ltd13a Ferndell St, South granvilleSYDNEY 2142AustraliaAUS
  • Phone+61 28865-2000
  • Fax+61 28865-2090
  • Websitehttps://www.cryosite.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cleo Diagnostics Ltd302.22k-3.92m13.71m----2.26--45.36-0.0305-0.03050.00240.0820.0502--3.76---65.13---76.78-------1,296.85-----28.110.00-------3,836.95------
Genetic Technologies Ltd8.49m-12.71m15.87m60.00--2.88--1.87-0.1126-0.11260.07520.04170.70289.844.20141,514.20-105.21-52.85-154.00-61.7053.5549.50-149.69-247.361.55--0.0736--27.83114.96-64.79--49.00--
Emyria Ltd1.95m-11.95m17.96m----18.91--9.21-0.0363-0.03630.00620.00260.275--49.60---168.58-77.78-321.66-93.49-12.45-45.04-612.98-388.17---30.010.7573---12.62--29.98------
Artrya Ltd0.00-11.56m24.40m----1.03-----0.1472-0.14720.000.30210.00-------36.17---38.11--------------0.0435------35.09------
Cryosite Ltd12.61m1.58m41.49m34.0026.3514.3317.903.290.03230.03230.25820.05930.591274.837.30--7.394.128.994.8860.8553.8812.508.562.29--0.4487--1.5115.043.30--10.72--
Microba Life Sciences Ltd6.54m-18.49m80.61m----1.64--12.32-0.0502-0.05020.01780.110.11192.679.26---31.64---37.61--46.55---282.64--3.11--0.0272--15.60---10.55------
Eureka Group Holdings Ltd39.24m17.71m161.44m42.009.121.098.714.110.05870.05870.130.49070.1626--64.27--7.346.027.546.2153.4350.4045.1333.60----0.384924.6222.4210.04134.41--91.86--
Data as of Apr 26 2024. Currency figures normalised to Cryosite Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.